Viewing Study NCT00050401



Ignite Creation Date: 2024-05-05 @ 11:29 AM
Last Modification Date: 2024-10-26 @ 9:08 AM
Study NCT ID: NCT00050401
Status: COMPLETED
Last Update Posted: 2017-09-01
First Post: 2002-12-08

Brief Title: Ventilator-Associated PneumoniaHospital-Acquired Pneumonia Requiring Mechanical Ventilatory Support
Sponsor: Pfizer
Organization: Pfizer

Study Overview

Official Title: Impact of Aggressive Empiric Antibiotic Therapy on the Emergence of Antimicrobial Resistance During the Treatment of Ventilator-associated Pneumonia
Status: COMPLETED
Status Verified Date: 2017-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: No
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of the study is to find out if high dose antibiotic meropenem MERREM IV along with another drug called an aminoglycoside a different type of antibiotic is effective in decreasing or reducing the rate of antibiotic resistant Pseudomonas aeruginosa Acinetobacter germs that can cause pneumonia and the rate of resistance in other difficult to treat germs which may cause hospital-acquired pneumonia requiring mechanical ventilatory support The study hopes to show that by increasing the amount of meropenem administered and increasing the duration of infusion release of the drug into the bloodstream levels of the drug will stay at target levels in the bloodstream and decrease the ability of difficult to treat germs to resist or not be killed by the treatment using this antibiotic meropenem or other antibiotics
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None